Neovascular Age-related Macular Degeneration Clinical Trials

16 recruiting

Neovascular Age-related Macular Degeneration Trials at a Glance

22 actively recruiting trials for neovascular age-related macular degeneration are listed on ClinicalTrialsFinder across 6 cities in 35 countries. The largest study group is Phase 3 with 8 trials, with the heaviest enrollment activity in Austin, Sacramento, and Augusta. Lead sponsors running neovascular age-related macular degeneration studies include Hoffmann-La Roche, Adverum Biotechnologies, Inc., and AbbVie.

Browse neovascular age-related macular degeneration trials by phase

Treatments under study

About Neovascular Age-related Macular Degeneration Clinical Trials

Looking for clinical trials for Neovascular Age-related Macular Degeneration? There are currently 16 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neovascular Age-related Macular Degeneration trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neovascular Age-related Macular Degeneration clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 22 trials

Recruiting
Phase 3

A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting
Phase 3

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled56 locationsNCT06847542
Recruiting
Phase 3

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Phase 3

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
AbbVie561 enrolled100 locationsNCT07007065
Recruiting
Phase 4

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Neovascular Age-related Macular Degeneration
Genentech, Inc.188 enrolled50 locationsNCT04853251
Recruiting

DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.

Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
Bayer50,000 enrolled1 locationNCT07308639
Recruiting

A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)

Neovascular Age-related Macular DegenerationDiabetic Macular Edema
Hoffmann-La Roche850 enrolled59 locationsNCT06680817
Recruiting
Early Phase 1

Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients

Neovascular Age-related Macular Degeneration
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine10 enrolled1 locationNCT07053358
Recruiting
Phase 3

Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting

Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)

Neovascular Age-related Macular DegenerationDiabetic Macular EdemaRetinal Vein Occlusion
Hoffmann-La Roche1,000 enrolled41 locationsNCT06439576
Recruiting
Phase 3

Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD

Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled64 locationsNCT05904028
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD

Neovascular Age-related Macular Degeneration
Innovent Biologics Technology Limited (Shanghai R&D Center)800 enrolled1 locationNCT07275840
Recruiting
Phase 1Phase 2

A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration
Sanofi66 enrolled18 locationsNCT06660667
Recruiting
Phase 2

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

Neovascular Age-Related Macular Degeneration (NVAMD)Branch Retinal Vein Occlusion (BRVO)
EyeBiotech Ltd.160 enrolled49 locationsNCT07205887
Recruiting
Phase 3

Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration

Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Not Applicable

Progression Suppression and Retinal Regression in VEGF-resistant AMD

Neovascular Age-related Macular Degeneration (AMD)
PharmaBio Corporation10 enrolled1 locationNCT07005323
Recruiting

Regulatory Post-Marketing Surveillance Study for Brolucizumab

Neovascular Age-related Macular Degeneration
Novartis Pharmaceuticals3,000 enrolled28 locationsNCT04985487
Recruiting
Phase 1Phase 2

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
Skyline Therapeutics (US) Inc.68 enrolled9 locationsNCT05986864
Recruiting
Phase 1

A Clinical Study Evaluating the Safety and Efficacy of SKG0106 in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Neovascular Age-related Macular Degeneration
Youxin Chen12 enrolled3 locationsNCT06213038